Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical Liver Disease

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cld.2017.08.010PMID 29128053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease.

  2016influential reference
• Lipid phenotypes in patients with nonalcoholic fatty liver disease.

  2016influential reference
• Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta‐analysis

  2016cited by this paper
• Prevalence of the metabolic syndrome in the United States, 2003-2012.

  2015cited by this paper
• Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

  2015cited by this paper
• PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome

  2014cited by this paper
• Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

  2014cited by this paper
• Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension.

  2014cited by this paper
• Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.

  2014influential reference
• Clinical association between non‐alcoholic fatty liver disease and the development of hypertension

  2014cited by this paper
• Circulating Triacylglycerol Signatures in Nonalcoholic Fatty Liver Disease Associated With the I148M Variant in PNPLA3 and With Obesity

  2013cited by this paper
• Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

  2013cited by this paper
• Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3

  2013influential reference
• Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States

  2013cited by this paper
• Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography.

  2013cited by this paper
• Association of Nonalcoholic Fatty Liver Disease With Components of Metabolic Syndrome According to Body Mass Index in Korean Adults

  2012cited by this paper
• Is visceral fat reduction necessary to favour metabolic changes in the liver?

  2012cited by this paper
• Paradoxical Lower Serum Triglyceride Levels and Higher Type 2 Diabetes Mellitus Susceptibility in Obese Individuals with the PNPLA3 148M Variant

  2012cited by this paper
• Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

  2011influential reference
• Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

  2011cited by this paper
• Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography.

  2011cited by this paper
• Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings

  2011cited by this paper
• Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity.

  2011influential reference
• Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

  2010cited by this paper
• Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease

  2010cited by this paper
• Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study

  2010influential reference
• The association of genetic variability in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease

  2010cited by this paper
• PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease

  2010cited by this paper
• Dissociation Between Fatty Liver and Insulin Resistance in Humans Carrying a Variant of the Patatin-Like Phospholipase 3 Gene

  2009cited by this paper
• Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As

  2009cited by this paper
• S1913 Visceral Fat As a Strong and Independent Risk Factor of Nonalcoholic Fatty Liver Disease

  2008cited by this paper
• Visceral fat: A key mediator of steatohepatitis in metabolic liver disease

  2008influential reference
• Visceral adipose tissue area is an independent risk factor for hepatic steatosis

  2008cited by this paper
• Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease.

  2008cited by this paper
• Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis

  2008cited by this paper
• Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

  2008cited by this paper
• Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome

  2008cited by this paper
• Fatty Liver: A Novel Component of the Metabolic Syndrome

  2007cited by this paper
• Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.

  2007influential reference
• Guidelines for the assessment and management of non‐alcoholic fatty liver disease in the Asia–Pacific region: Executive summary

  2007cited by this paper
• The Severity of Ultrasonographic Findings in Nonalcoholic Fatty Liver Disease Reflects the Metabolic Syndrome and Visceral Fat Accumulation

  2007cited by this paper
• Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease

  2006cited by this paper
• Metabolic and behavioral characteristics of metabolically obese but normal-weight women.

  2004influential reference
• Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

  2003influential reference
• Increased visceral fat and serum levels of triglyceride are associated with insulin resistance in Japanese metabolically obese, normal weight subjects with normal glucose tolerance.

  2003cited by this paper

• The contested association between MASLD and osteoporosis: a narrative review of heterogeneous evidence and modifying factors

  2026cites this paper
• Regulation of hepatic Sirt1 expression and lipid metabolism through TNF receptor signaling

  2025cites this paper
• The Rising Global Burden of MASLD and Other Metabolic Diseases (2000–2021)

  2025cites this paper
• Thyroid dysfunction in liver pathology

  2025cites this paper
• The Ability of the Triglyceride-Glucose (TyG) Index and Modified TyG Indexes to Predict the Presence of Metabolic-Associated Fatty Liver Disease and Metabolic Syndrome in a Pediatric Population with Obesity

  2025cites this paper
• Non alkolik yağlı karaciğer hastalığı ile kafein alımı arasındaki ilişki

  2025cites this paper
• Effects of short-term very low-calorie diet on metabolic profile in patients with metabolic syndrome

  2025cites this paper
• Insights Into Non-Alcoholic Fatty Liver Disease and Diabetes Mellitus in Somalia: Prevalence and Risk Factors

  2025cites this paper
• Mendelian randomization analysis of smoking, BMI, and nonalcoholic fatty liver disease in European descent populations

  2025cites this paper
• Prevalence and Risk Factors of Metabolic Dysfunction–Associated Steatotic Liver Disease in Patients With Type 2 Diabetes Mellitus at a Tertiary Center in Saudi Arabia: Cross-Sectional Questionnaire Study

  2025cites this paper
• Doppler assessment of portal and hepatic vein alterations in non-alcoholic fatty liver disease

  2025cites this paper
• Promising effects of Persian shallot extract on the serum markers and blood pressure of patients with metabolic syndrome: a double-blinded randomized controlled trial.

  2025cites this paper
• Reduced risk of hepatocellular carcinoma in the use of fibrate as an add-on to statin: A retrospective population-based cohort study.

  2025cites this paper
• Cell models to probe the biological bases of Antipsychotic-induced Metabolic Syndrome: towards an individual specific approach.

  2025cites this paper
• Lipid metabolism indicators provide tools for the diagnosis of non-alcoholic fatty liver disease: results of a nationwide survey

  2025cites this paper
• Frequency and risk factors of metabolic associated fatty liver disease among medical students in Egypt

  2025cites this paper
• Quercetin and Camellia sinensis leaf extract ameliorates liver steatosis in high-fat diet fed mice via suppression of oxidative stress and inflammation

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease: A silent pandemic

  2024cites this paper
• Non-Alcoholic Fatty Liver Disease May Be a Risk Factor for Liver Metastasis After Radical Surgery for Colorectal Cancer: A Retrospective Study

  2024cites this paper
• Is MAFLD better than NAFLD in predicting the risk of major cardiovascular diseases? Evidence from a 7-year prospective cohort study.

  2024cites this paper
• Elevated LDL-c may warn of the risk of gallbladder stones in the patients with metabolic dysfunction-associated steatotic liver disease: A case-control study.

  2024cites this paper
• Association between weight-adjusted waist index and non-alcoholic fatty liver disease: a population-based study

  2024cites this paper
• The Impact of Metabolic Bariatric Surgery on Cardiovascular Diseases in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease

  2024cites this paper
• Association between nonalcoholic fatty liver disease and increased glucose-to-albumin ratio in adults without diabetes

  2024cites this paper
• Exploring the interplay of gut microbiota, inflammation, and LDL-cholesterol: a multiomics Mendelian randomization analysis of their causal relationship in acute pancreatitis and non-alcoholic fatty liver disease

  2024cites this paper
• Non-alcoholic fatty liver disease among people living with HIV on long-term antiretroviral therapy in Indonesia: Prevalence and related factors

  2024cites this paper
• Research Progress on Non-Alcoholic Fatty Liver Disease

  2024cites this paper
• Role of the angiopoietin-like protein family in the progression of NAFLD

  2024cites this paper
• Prevalence trends of type 2 diabetes treatment, dyslipidemia and hepatic steatosis in Northeast Germany.

  2024cites this paper
• MASLD-Related Hepatocarcinoma: Special Features and Challenges

  2024cites this paper
• Assessment Prevalence of Thrombocytopenia in Chronic Hepatitis B and C

  2024cites this paper
• Diagnostic Accuracy of Transient Elastography in Hepatosteatosis in Youth With Obesity

  2024cites this paper
• Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations

  2024cites this paper
• Monocyte to High-density Lipoprotein Cholesterol Ratio as a Predictor of Nonalcoholic Fatty Liver Disease in Childhood Obesity

  2024cites this paper
• Association between obesity phenotypes and non-alcoholic fatty liver: a large population- based study

  2024cites this paper
• Study on the molecular mechanisms of rifaximin in the treatment of non‑alcoholic steatohepatitis based on the Helicobacter‑DCA‑Fxr‑Hnf1α signalling pathway

  2024cites this paper
• Lactate dehydrogenase is associated with flow-mediated dilation in hypertensive patients

  2023cites this paper
• Combining serum uric acid and fatty liver index to improve prediction quality of nonalcoholic fatty liver disease

  2023cites this paper
• Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa

  2023cites this paper
• Polysaccharides from Ostrea rivularis rebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice.

  2023cites this paper
• HbA1c of 5.8% or higher as the most useful indicator for recommendation of ultrasonography to detect nonalcoholic fatty liver disease

  2023cites this paper
• Harnessing Polarity-Dependent Fluorescent Probe for Lipid Droplet Metabolism Dissection and in vivo Nonalcoholic Fatty Liver Disease Diagnosis

  2023cites this paper
• Nonalcoholic fatty liver disease and cognitive impairment: A prospective cohort study

  2023cites this paper
• Can Cardiometabolic Risk Be Reduced in the Elderly? Comprehensive Epidemiological Study

  2023cites this paper
• Development of the national bariatric prioritization tool in Aotearoa New Zealand

  2023cites this paper
• Distinct Morphological and Molecular Profiles of NAFLD and NAFLD-associated HCC Revealed by Immunohistochemistry and MicroRNA Analysis.

  2023cites this paper
• An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand

  2023cites this paper
• Non-Alcoholic Fatty Liver Disease and Bone Tissue Metabolism: Current Findings and Future Perspectives

  2023influential citation
• Chaperone-mediated autophagy dysregulation during aging impairs hepatic fatty acid oxidation via accumulation of NCoR1

  2023cites this paper
• Mechanisms of non-alcoholic fatty liver disease development in normal-weight individuals

  2023cites this paper
• Sound Explanation for Trustworthy Machine Learning

  2023cites this paper
• Prevalence of metabolic syndrome among Vietnamese adult employees.

  2023cites this paper
• Thyroid hormone receptor-beta agonists in NAFLD therapy: possibilities and challenges.

  2023cites this paper
• The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study

  2023cites this paper
• Metabolic role of hepassocin in polycystic ovary syndrome.

  2023cites this paper
• Waist to Height Ratio in Nonalcoholic Fatty Liver Disease - Systematic Review and Meta-analysis.

  2023cites this paper
• Dyslipidemia and impaired liver function biomarkers in patients with hepatitis B liver cirrhosis

  2023cites this paper
• Poor cardiorespiratory fitness may be an indicator of more severe liver inflammation in non-alcoholic fatty liver disease patients.

  2023cites this paper
• Sodium Propionate or Sodium Butyrate Promotes Fatty Acid Oxidation in HepG2 Cells Under Oxidative Stress

  2023cites this paper
• Health associations of liver enzymes and inflammatory scores with urinary citrus flavonoid metabolites

  2022cites this paper
• Diabetes in general

  2022cites this paper
• Ethanol Extracts of Eriobotrya japonica (Loquat) Seeds, Leaves, and Fruits Have Anti-obesity and Hypolipidemic Effects in Rats

  2022cites this paper
• Ideal Cardiovascular Health Metrics Are Associated with Reduced Severity of Hepatic Steatosis and Liver Fibrosis Detected by Transient Elastography

  2022cites this paper
• Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

  2022cites this paper
• Metabolomics analysis of the serum metabolic signature of the nonalcoholic fatty liver disease combined with prediabetes model rats after the intervention of Lycium barbarum polysaccharides combined with aerobic activity.

  2022cites this paper
• Obesity, but not glycemic control, predicts liver steatosis in children with type 1 diabetes.

  2022cites this paper
• Dislipidemias, hígado graso y enfermedad cardiovascular

  2022cites this paper
• Association of Bariatric Surgery With Cardiovascular Outcomes in Adults With Severe Obesity and Nonalcoholic Fatty Liver Disease

  2022cites this paper
• Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation Parameter

  2022cites this paper
• Updates in interaction of gastroesophageal reflux disease and extragastroesophageal digestive diseases

  2022cites this paper
• Relation between non-alcoholic fatty liver disease and atherosclerosis

  2022cites this paper
• Croton urucurana Baill. Ameliorates Metabolic Associated Fatty Liver Disease in Rats

  2022cites this paper
• Small-Molecule Inhibitors Targeting Lipolysis in Human Adipocytes

  2022cites this paper
• Non-Alcoholic Fatty Liver Disease and the Risk of Diabetes Mellitus by Menopausal Status: A Nationwide Cohort Study

  2022cites this paper
• Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids

  2022cites this paper
• Early unhealthy eating habits underlie morpho-functional changes in the liver and adipose tissue in male rats

  2022cites this paper
• Effects of Different Scan Projections on the Quantitative Ultrasound-Based Evaluation of Hepatic Steatosis

  2022cites this paper
• Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease

  2022cites this paper
• Long-term surgical outcomes of Non alcoholic fatty liver disease associated hepatocellular carcinoma.

  2022cites this paper
• Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series

  2022cites this paper
• Sirt1 Promotes the Restoration of Hepatic Progenitor Cell (HPC)-Mediated Liver Fatty Injury in NAFLD Through Activating the Wnt/β-Catenin Signal Pathway

  2021cites this paper
• The albumin-to-alkaline phosphatase ratio as an independent predictor of future non-alcoholic fatty liver disease in a 5-year longitudinal cohort study of a non-obese Chinese population

  2021cites this paper
• Glucose participates in the formation of goose fatty liver by regulating the expression of miRNA-33/CROT.

  2021cites this paper
• Non-Alkolik Yağlı Karaciğer Hastalığında Potansiyel Tedavi Yaklaşımı: E Vitamini

  2021cites this paper
• Non-alcoholic fatty liver disease and lipotoxicity

  2021cites this paper
• Association between Monocyte to High-Density Lipoprotein Cholesterol Ratio and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study

  2021cites this paper
• Risk of Glaucoma Associated with Components of Metabolic Disease in Taiwan: A Nationwide Population-Based Study

  2021cites this paper
• Influence of irisin on diet-induced metabolic syndrome in experimental rat model

  2021cites this paper
• Neochlorogenic Acid Attenuates Hepatic Lipid Accumulation and Inflammation via Regulating miR-34a In Vitro

  2021cites this paper
• Low Density Lipoprotein Cholesterol May Be a Key Independent Risk Factor for Asymptomatic Gallbladder Stone Disease in Non-Alcoholic Fatty Liver Disease Patients in Northwest China: A Case-Control Study

  2021cites this paper
• Systematic analysis of the pharmacological function of Schisandra as a potential exercise supplement

  2021cites this paper
• Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients

  2021cites this paper
• Metabolic Syndrome in Adults with Nonalcoholic Fatty Liver Disease

  2021cites this paper
• Lipolysis: cellular mechanisms for lipid mobilization from fat stores

  2021cites this paper
• The curative effect of metformin and linagliptin in newly-diagnosed type 2 diabetes patients with non-alcoholic fatty liver disease

  2021cites this paper
• Association of VEGF +405 C > G (rs2010963) polymorphism with susceptibility of metabolic syndrome: Cardio-metabolic risk factors and serum Matrix Metaloproteinase-3 concentrations

  2021cites this paper
• Endocrine Disrupting Chemicals-induced Metabolic Disorders and Treatment Strategies

  2021cites this paper
• Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach

  2021cites this paper
• Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

  2021cites this paper
• Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver

  2021cites this paper